Allele, SCM partner to develop iPS cell therapies for diabetes

Allele Biotechnology and SCM partnered to develop diabetes therapies using pancreatic beta cells derived from induced pluripotent stem (iPS) cells.

Allele Biotechnology & Pharmaceuticals Inc. (San Diego, Calif.) will be responsible for developing the pancreatic beta cells using its mRNA platform for generation and differentiation of iPS cells. Deal terms were not disclosed...